Skip to Main Content

Paper Details

Phase II trial of fulvestrant plus enzalutamide in ER+/HER2- advanced breast cancer.
NPJ Breast Cancer
2
2023
AKT, AR, BC, CBR24, ER, ER+, ER+/HER2-, ER+/HER2- BC, Enzalutamide, Fulvestrant, HER2, PI3K, PIK3CA, PTEN mutations, advanced breast cancer, biopsies, breast cancer, enzalutamide, fulvestrant, mTOR, metastatic, metastatic BC, patients, tumor, visceral disease, women
Author NameAffiliation
Kathryn L ZolmanUniversity of Colorado Anschutz Medical Campus
Adrie van BokhovenUniversity of Colorado Anschutz Medical Campus
Emanuel F PetricoinCenter for Applied Proteomics and Molecular Medicine, George Mason University
Emanuel F PetricoinCenter for Applied Proteomics and Molecular Medicine, George Mason University
Dexiang GaoUniversity of Colorado Anschutz Medical Campus
  • 1 - 5

Datasets

Release 1.2